PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Bernhardt, A.M.* ; Tiedt, S.* ; Teupser, D.* ; Dichgans, M.* ; Meyer, B.* ; Gempt, J.* ; Kuhn, P.H.* ; Simons, M.* ; Palleis, C.* ; Weidinger, E.* ; Nübling, G.* ; Holdt, L.* ; Hönikl, L.* ; Gasperi, C.* ; Giesbertz, P.* ; Müller, S.A.* ; Breimann, S.* ; Lichtenthaler, S.F.* ; Kuster, B.* ; Mann, M.* ; Imhof, A.* ; Barth, T.* ; Hauck, S.M. ; Zetterberg, H.* ; Otto, M.* ; Weichert, W.* ; Hemmer, B.* ; Levin, J.*

A unified classification approach rating clinical utility of protein biomarkers across neurologic diseases.

EBioMedicine 89:104456 (2023)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
A major evolution from purely clinical diagnoses to biomarker supported clinical diagnosing has been occurring over the past years in neurology. High-throughput methods, such as next-generation sequencing and mass spectrometry-based proteomics along with improved neuroimaging methods, are accelerating this development. This calls for a consensus framework that is broadly applicable and provides a spot-on overview of the clinical validity of novel biomarkers. We propose a harmonized terminology and a uniform concept that stratifies biomarkers according to clinical context of use and evidence levels, adapted from existing frameworks in oncology with a strong focus on (epi)genetic markers and treatment context. We demonstrate that this framework allows for a consistent assessment of clinical validity across disease entities and that sufficient evidence for many clinical applications of protein biomarkers is lacking. Our framework may help to identify promising biomarker candidates and classify their applications by clinical context, aiming for routine clinical use of (protein) biomarkers in neurology.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
11.100
0.000
2
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Analytical Validity ; Biomarker ; Clinical Utility ; Neurology ; Protein ; Proteomics; Fibrillary Acidic Protein; Alzheimers-disease; Cerebrospinal-fluid; Multiple-sclerosis; Alpha-synuclein; Neurofilament Light; Serum Biomarkers; Diagnosis; Csf; Marker
Sprache englisch
Veröffentlichungsjahr 2023
HGF-Berichtsjahr 2023
ISSN (print) / ISBN 2352-3964
e-ISSN 2352-3964
Zeitschrift EBioMedicine
Quellenangaben Band: 89, Heft: , Seiten: , Artikelnummer: 104456 Supplement: ,
Verlag Elsevier
Verlagsort Amsterdam [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) CF Metabolomics & Proteomics (CF-MPC)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-505700-001
Förderungen Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
Munich Cluster for Systems Neurology
BMBF
DOI 10.1016/j.ebiom.2023.104456
WOS ID 000968658100001
Scopus ID 85147819736
PubMed ID 36745974
Erfassungsdatum 2023-02-18
[➜Korrektur melden]